Eidogen-Sertanty

Executive Summary

Eidogen-Sertanty is a US-based provider of AI-powered software and knowledgebases for drug discovery, founded in 2001 and headquartered in San Diego. The company specializes in platforms such as the Kinase Knowledgebase (KKB), Oncology Knowledgebase (OKB), and Target Informatics Platform (TIP), which aggregate and analyze vast biological, chemical, and structural data to accelerate target identification and validation. Despite operating in the competitive AI drug discovery space, the company has established a niche by offering curated, domain-specific knowledgebases that enhance the efficiency of pharmaceutical R&D. With no disclosed funding or valuation, Eidogen-Sertanty appears to be a self-sustained, bootstrapped entity, which may limit its growth trajectory but also indicates operational discipline. The company's long history and specialized focus position it as a potential partner for biopharma firms seeking to leverage AI for early-stage discovery, though its impact is constrained by a lack of publicly reported commercial traction or large-scale partnerships. If the company can secure strategic collaborations or expand its platform capabilities, it could capture a larger share of the growing AI drug discovery market.

Upcoming Catalysts (preview)

• Q4 2026Announcement of a major partnership with a top-20 pharmaceutical company35% success
• Q2 2027Release of a new AI-powered module for target identification in immunology40% success
• Q1 2027Publication of validation study demonstrating improved hit rates using TIP platform50% success